News
-
-
-
-
-
PRESS RELEASE
Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Formycon AG initiates Phase III clinical trial for FYB206, a Keytruda biosimilar, in NSCLC patients in Eastern Europe and Southeast Asia. Study aims to compare safety and efficacy with Keytruda -
-
-
-
-
PRESS RELEASE
Audited Annual Statements for the Fiscal Year ended March 31, 2024
Plaintree Systems Inc. (CSE:NPT) releases audited annual statements for fiscal year ending March 31, 2024, reporting increased revenues and profit. Company offers diversified product lines in Specialty Structures and Applied Electronics